Arde­lyx steps up with a bet­ter round of PhI­II da­ta to com­pare with ri­vals at Iron­wood, Syn­er­gy

Arde­lyx $ARDX is tak­ing a sec­ond shot at mak­ing a bad­ly need­ed good late-stage im­pres­sion with their lead drug for ir­ri­ta­ble bow­el syn­drome with con­sti­pa­tion, rolling out a new round of promis­ing Phase III da­ta for their lead drug tena­panor.

In a tough field like IBS-C, im­press­ing an­a­lysts is no easy task. But at first blush in­vestors loved the news, dri­ving up shares 56% this time.

When Arde­lyx ex­ecs rolled out their first round of Phase III da­ta on their IBS drug tena­panor, they were con­fi­dent that they were play­ing a win­ning hand, with sta­tis­ti­cal­ly sig­nif­i­cant re­sults in beat­ing out a place­bo for eas­ing ab­dom­i­nal pain and in­creas­ing bow­el move­ments.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER